Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib for Residual Contralateral Nodules in EGFR-Mutant sMPLC
NCT06924398Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Secondary Surgery Rate at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06924398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924398.